Quick Answer
Anika Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $57.48 million for the year ending 2025.
- Anika Therapeutics, Inc. showed an increase of +3.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Anika Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), Anika Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 33.1%.
- Historical annual values: Fiscal year 2025: $57.48 million | Fiscal year 2024: $55.63 million | Fiscal year 2023: $68.74 million | Fiscal year 2022: $86.33 million | Fiscal year 2021: $94.39 million | Fiscal year 2020: $95.82 million | Fiscal year 2019: $157.46 million | Fiscal year 2018: $89.04 million | Fiscal year 2017: $133.26 million | Fiscal year 2016: $104.26 million | Fiscal year 2015: $110.71 million | Fiscal year 2014: $100.16 million | Fiscal year 2013: $63.33 million | Fiscal year 2012: $44.07 million | Fiscal year 2011: $35.78 million | Fiscal year 2010: $28.20 million | Fiscal year 2009: $24.43 million | Fiscal year 2008: $43.19 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: